Products & Services
Research & Specialties
Custom Peptide Synthesis
Amino Acid Derivatives
Services & Capabilities
Quality & Regulatory
Research Grade Production
Supply & vertical integration
Our vision & strategy
People & culture
Safeguarding the environment
Investors & Media
Reports & Presentations
News & Events
Half-Year Report 2019: Record sales of 134.5 million CHF and surge in operating income in the first half
August 23, 2019
Significant sales and EBIT growth
EBITDA at 27.1% and EBIT at 18.2% of sales
Capital increase boosts equity ratio
Potentially record-breaking second half expected
Annual targets confirmed
Another strong fiscal year anticipated
Peptide Trends July 2019
Peptide Trends August 2019
The weight loss drug Liraglutide
Interview with Amy Zhang, Head of Supply Chain at Luye Pharma
What are oligonucleotides?
Somatostatin Analogues Provide Invaluable Therapeutic Options
What are somatostatin and somatostatin analogues?
Bachem innovating through virtual events
Meet Bachem: Pascal Hess, Group Leader Generics – Portfolio
A world market leader from the Basel region – Bachem celebrates 50 years of company history
What are Amino Acids?
Bachem recognized as a winner at the Swiss Biotech Success Stories Awards 2021
What is GMP?
Will Targeting Alpha-Synuclein Lead to Treatments for Parkinson’s Disease?
Meet Bachem: Swetlana Meinhardt, Category Manager
Peptides unlock doors to understand Parkinson’s disease
Interview with Robert Yu, CEO of Yuyu Pharma
What are peptides?
Bachem celebrates the hire of its 1000th employee at the Bubendorf site
GalNAc: Delivering Promise of Oligonucleotides
Bachem appoints new Head of Group Communications
Meet Bachem: Johannes Kremser, Group Leader R&D